Stocktoria

BIOGEN INC. BIIB

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1991-09-17 · LEI

BIOGEN INC. financials (annual)

Revenue
$11.45B $12.27B $13.45B $14.38B $13.44B $10.98B $10.17B $9.84B $9.68B $9.89B 2016201720182019202020212022202320242025
Net income
$3.70B $2.54B $4.43B $5.89B $4.00B $1.56B $3.05B $1.16B $1.63B $1.29B 2016201720182019202020212022202320242025
Free cash flow
$3.97B $3.68B $5.42B $6.56B $3.81B $3.38B $1.14B $1.27B $2.72B $2.05B 2016201720182019202020212022202320242025

Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$9.9B$9.7B$9.8B$10.2B$11.0B$13.4B$14.4B$13.5B$12.3B$11.4B
Gross profit—————$11.6B$12.4B$11.6B$10.6B$10.0B
SG&A expense$2.4B$2.4B$2.5B$2.4B$2.7B$2.5B$2.4B$2.1B$1.9B$1.9B
Operating income————$2.8B$4.6B$7.0B$5.9B$5.3B$5.2B
Interest expense$267.5M$250.3M$246.9M$246.6M$253.6M$222.5M$187.4M$200.6M$250.8M$260.0M
Income tax$263.6M$273.8M$135.3M$632.8M$52.5M$992.3M$1.2B$1.4B$2.5B$1.2B
Net income$1.3B$1.6B$1.2B$3.0B$1.6B$4.0B$5.9B$4.4B$2.5B$3.7B
EPS (diluted)$8.79$11.18$7.97$20.87$10.40$24.80$31.42$21.58$11.92$16.93
Operating cash flow$2.2B$2.9B$1.5B$1.4B$3.6B$4.2B$7.1B$6.2B$4.6B$4.6B
Free cash flow$2.1B$2.7B$1.3B$1.1B$3.4B$3.8B$6.6B$5.4B$3.7B$4.0B
Cash & equivalents——————$2.9B$1.2B$1.6B$2.3B
Inventory$2.2B$2.5B$2.5B$1.3B$1.4B$1.1B$804.2M$929.9M$902.7M$1.0B
Total assets$29.4B$28.0B$26.8B$24.6B$23.9B$24.6B$27.2B$25.3B$23.7B$22.9B
Total liabilities$11.2B$11.3B$12.0B$11.2B$12.9B$13.9B$13.9B$12.3B$11.1B$10.7B
Shareholders' equity$18.3B$16.7B$14.8B$13.4B$11.0B$10.7B$13.3B$13.0B$12.6B$12.1B

Growth · year-over-year · Revenue CAGR -1.6%

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue growth+2.2%-1.6%-3.3%-7.4%-18.3%-6.5%+6.9%+9.6%+7.2%+6.4%
Net income growth-20.8%+40.6%-61.9%+95.8%-61.1%-32.1%+32.9%+74.5%-31.4%+4.4%
EPS growth-21.4%+40.3%-61.8%+100.7%-58.1%-21.1%+45.6%+81.0%-29.6%+10.4%
Free cash flow growth-24.7%+114.3%+11.0%-66.2%-11.1%-42.0%+21.2%+47.1%-7.2%+21.2%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.